Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.

Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control? New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb. Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC

Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK

• EULAR Abstract Archive

Combined Nordic registry data on demyelination and inflammatory neuropathy with TNFi. Demyelination 2-3 times higher in SpA vs RA. No difference between ETN and monoclonals. @RheumNow #EULAR2022 OP0060 https://t.co/SK9s7aVaZk https://t.co/hZ5VaoTe4X

• EULAR Abstract Archive

Combined nordic registers study: 🧠 demyelinating and inflammatory neuropathies in 50000+ patients starting TNFi 📍DML SpA > RA 📍INP SpA = RA 📍ETA = Other anti TNFi But no csDMARDs control group OP0060 #EULAR2022 @RheumNow https://t.co/LYqUW22rMg

Combination tx of NSAIDs and TNFi (celecoxib and golimumab) did not show significant superiority compared to TNFi alone in slowing radiographic progression for treatment of radiographic axSpA. There was a numerical reduction however. #EULAR2022 @RheumNow #ABSTOP0018 https://t.co/gUZAwd92dK